1,402 reports of this reaction
2.8% of all PAZOPANIB HYDROCHLORIDE reports
#8 most reported adverse reaction
VOMITING is the #8 most commonly reported adverse reaction for PAZOPANIB HYDROCHLORIDE, manufactured by Novartis Pharmaceuticals Corporation. There are 1,402 FDA adverse event reports linking PAZOPANIB HYDROCHLORIDE to VOMITING. This represents approximately 2.8% of all 49,320 adverse event reports for this drug.
Patients taking PAZOPANIB HYDROCHLORIDE who experience vomiting should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VOMITING is a less commonly reported adverse event for PAZOPANIB HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to vomiting, the following adverse reactions have been reported for PAZOPANIB HYDROCHLORIDE:
The following drugs have also been linked to vomiting in FDA adverse event reports:
VOMITING has been reported as an adverse event in 1,402 FDA reports for PAZOPANIB HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
VOMITING accounts for approximately 2.8% of all adverse event reports for PAZOPANIB HYDROCHLORIDE, making it a notable side effect.
If you experience vomiting while taking PAZOPANIB HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.